Meet Delic Corp, The Largest Ketamine Clinic Network in the U.S.
Similar Posts
Are Ketamine Infusions Addictive?
It is understandable that people are apprehensive about ketamine use considering its well-known misuse. However, when administered under the direction of a medical professional for depression or other mental health related treatment, ketamine does not seem to be addictive in any way.
The Spotlight Roundup-The First-Ever Female Founded Psychedelic Company
July 7, 2021- This week’s Psychedelic Business News top stories…
Will MindMed (MMED) join the NASDAQ? (What Will Happen To the Stock If It Does?)
Will MindMed get uplisted on the NASDAQ and what will happen to its stock price if the company is accepted? These are all questions we’ve been wondering 😱.
The requirements to join NASDAQ have been less than clear for investors. It has been more than six weeks since MindMed (MMED) applied for an uplisting on NASDAQ and retail investors have been waiting for news while MindMed’s stock price has been reaching all times highs🔥. In this video, we’ll discuss what the actual requirements are, what will happen to MMED’s stock price if the company gets uplisted, and whether retail investors should be influenced by the news ( good or bad).
Hope you guys enjoy this video!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #mmed #mindmedstock
Resources: https://www.thestreet.com/investing/nasdaq-listing-requirements-15092402?fbclid=IwAR09DXpV8nLoMgXrJ7Ru1A8GHk53BHQBakLFI1xnHLw-ZDzY7nZjp88D0CU
Andrew Yang Supports LEGALIZING PSILOCYBIN in New York (But Can He Do It?)
Hello psychedelic investors! Today’s episode is a bit different yet still relevant to all of us invested in the psychedelic industry!
To summarize,
Andrew Yang comes out Hard against the war on drugs and for legalizing psilocybin. He says “The war on drugs has been a war on people”.
Specifically, Andrew Yang calls out the criminalization of opioid use, saying big pharma has gotten these people addicted while “generating billions of dollars of blood money”, and then we throw people in jail for the pharma industries failures.
This is, in Yang’s eyes, not a criminal problem, but a public health problem.
If people are addicted to something, don’t throw them in jail, get them the help that they need to treat an illness that in many cases was caused by billionaire pharma companies.
How will Andrew Yang create a de facto decriminalization?
He would instruct the DA not to prosecute for possession charges.
Its that simple.
Finally he talks about how he is for the legalization of psilocybin and open to legalize other substances.
Yang is calling for decriminalizing the use of all drugs, AND to legalize psilocybin..
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
For any collaborations, you can reach us on our email
email: thepsychedelicinvestor@gmail.com
If you are thinking of joining Benzinga Pro, why not use our link, and we will both get a discount!
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#AndrewYang #AndrewYangMayor #AndrewYangDebate
Psychedelics, Neuroscience & Big Pharma – Interview with Rob Barrow | MindMed
In this episode of Psychedelic Spotlight, Matt sits down with…
MindMed Releases LSD for Anxiety Data ! (MNMD, MMED)
Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd:
www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20
Join our Newsletter (scroll to the bottom of the page and sign up):
https://psychedelicspotlight.com/
Follow us on Twitter:
The Psychedelic Investor: @PSYCBiz
Psychedelic Spotlight: @PsycSpotlight
Follow us on Instagram:
@psycbiz
@psycspotlight
❗❗❗ The Psychedelic Investor will be changing its name to PSYC Business very soon.
Stay tuned for more updates!
In today’s episode, we discuss MindMed (Nasdaq: MNMD, NEO:MMED) and its Phase 2 LSD Trial Treating Anxiety Results.
MindMed (Nasdaq: MNMD, NEO:MMED) finally gave the world a glimpse into its LSD-as-medicine project today.
Speaking at the highly anticipated PSYCH Symposium in London, researchers Prof. Matthias Liechti and Dr. Friederike Holze presented topline data of a Phase 2, double-blind, placebo-controlled study, attempting to treat anxiety disorders with LSD in 46 patients. Patients received 200 µg (micrograms) of LSD, which is considered a large dose.
The results were very positive, though perhaps not paradigm shifting — yet.
The primary endpoint of the study was the reduction in anxiety levels 16 weeks after the administration of LSD. They measured this using a questionnaire called the State Trait Anxiety Inventory, better known by its acronym STAI. In short, a person can have a score between 0 and 63, with the higher the score, the worse the anxiety.
The study found that 65% of patients saw their anxiety levels drop by at least 30% from where they were before treatment, 16 weeks after dosing. This compared to only 9% of patients in the placebo arm reaching that 30% level. The average reduction in the STAI was 16.2 points.
Importantly, there was only one serious adverse event in the trial, which consisted of “acute transient anxiety and delusions” during the LSD experience. It does not appear that this patient had any troubles once the effects wore off. In sum, the administration of large doses of LSD appears to be very safe, even if one person did have a particularly bad experience during the dosing.
Furthermore, when looking at secondary variables that measure depression, anxiety and other major psychiatric symptoms (Hamilton Depression Scale, Beck Depression Index, Symptom-Check-List-90-R) the results “showed similarly rapid and sustained responses consistent with a lasting treatment effect.”
In sum, according to MindMed, the topline data demonstrates “the significant, rapid, durable, and beneficial effects of LSD and potential to safely mitigate symptoms of anxiety and depression.”
Interested in reading the article? Click here: 👇
MindMed’s Phase 2 LSD Trial Treating Anxiety Was a Success
https://psychedelicspotlight.com/mindmed-lsd-anxiety-phase-2-trial-psych-symposium/
#MindMed #Anxiety #MNMD